Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 7/20 | 0.81 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 7/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849764 | 1.00 | PRCP (0.81) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14856996 | 1.00 | PRCP (0.81) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14849804 | 0.93 | PRCP (0.69) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14849873 | 0.93 | PRCP (0.69) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14849752 | 0.90 | PRCP (0.66) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14849783 | 0.90 | PRCP (1.00) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14849781 | 0.90 | PRCP (1.00) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14849684 | 0.80 | PRCP (0.81) | PRCPMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16512626 | 0.73 | PRCP (0.50) | PRCPTGFBR1 | |
| SCHEMBL14849801 | 0.71 | PRCP (0.76) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006268-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006268-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130090324-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| US-20130090324-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| WO-2011156246-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090324-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885MAPK13 2672/4885MAPK12 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.